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Abstract
Extent of coronary atherosclerotic disease (CAD) burden on coronary computed tomography angiography (CCTA) as meas-
ured by segment involvement score (SIS) has a prognostic value. We sought to investigate the incremental prognostic value 
of ‘age adjusted SIS’ (aSIS), which may be a marker of premature atherosclerosis and vascular age. Consecutive patients 
were prospectively enrolled into the CONFIRM (Coronary CT Angiography EvaluatioN For Clinical Outcomes: An InteR-
national Multicentre) multinational observational study. Patients were followed for the outcome of all-cause death. aSIS 
was calculated on CCTA for each patient, and its incremental prognostic value was evaluated. A total of 22,211 patients 
[mean age 58.5 ± 12.7 years, 55.8% male) with a median follow-up of 27.3 months (IQR 17.8, 35.4)] were identified. After 
adjustment for clinical factors and presence of obstructive CAD, higher aSIS was associated with increased death on mul-
tivariable analysis, with hazard ratio (HR) 2.40 (1.83–3.16, p < 0.001), C-statistic 0.723 (0.700–0.756), net reclassification 
improvement (NRI) 0.36 (0.26–0.47, p < 0.001), and relative integrated discrimination improvement (IDI) 0.33 (p = 0.009). 
aSIS had HR 3.48 (2.33–5.18, p < 0.001) for mortality in those without obstructive CAD, compared to HR 1.79 (1.25–2.58, 
p = 0.02) in those with obstructive CAD. In conclusion, aSIS has an incremental prognostic value to traditional risk factors 
and obstructive CAD, and may enhance CCTA risk stratification.
Keywords Coronary · Computed tomography · Atherosclerosis · Prognosis
Introduction
Coronary computed tomography angiography (CCTA) is 
recommended in symptomatic individuals for the detection 
and exclusion of coronary artery disease (CAD) [1], and 
has a prognostic value [2–4]. Increasing extent of coronary 
atherosclerosis, as quantified by segment involvement score 
(SIS) or the synonymous total plaque score (TPS), has been 
shown to be a predictor of clinical events [5–7]. Rate of 
development of atherosclerotic disease has been shown to 
be a better predictor of adverse clinical outcomes [8–10]. 
Hence we devised a score ‘age adjusted SIS’ (aSIS), which 
standardizes SIS to the number of evaluable segments and 
normalizes it to patient age. We hypothesize that aSIS is a 
surrogate marker of ‘vascular age’, as it gives greater weight-
ing to segments involved in those who are younger, and so 
may account for premature atherosclerotic disease.
Previous work demonstrated that aSIS (or as previously 
termed %TPS/age) had an incremental prognostic value 
over risk factors and obstructive CAD for MACE [11]. We 
sought to externally validate the prognostic value of aSIS in 
the large prospective multinational CONFIRM (COronary 
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Computed Tomography Angiography Evaluation for Clini-
cal Outcomes: An InteRnational Multicentre Registry) 
cohort.
Materials and methods
Study population
Consecutive patients undergoing CCTA were prospectively 
enrolled into the CONFIRM (COroNary CT Angiogra-
phy Evaluation For Clinical Outcomes: An InteRnational 
Multicenter Registry). The design of the registry has been 
described in depth previously [12]. Inclusion criteria were 
adults (≥ 18 years) referred for clinically suspected CAD 
who underwent ≥ 64-detector row CCTA examination 
between February 2003 and September 2010 in twelve cent-
ers in six countries (Canada, Germany, Italy, Korea, Swit-
zerland, and the United States). This study complies with 
the Declaration of Helsinki, and all centers had institutional 
review board approval for patient enrollment and follow-up. 
Only patients who provided informed consent were included.
Patients with a history of heart transplantation and 
congenital heart disease were excluded. To ensure there 
was no duplication of patients, we removed patients who 
had been analyzed in our previous study [11]. In addi-
tion, patients with < 11 segments reported (n = 6464) and 
patients who had missing information about clinical risk 
factors were removed from analysis. After excluding 7410 
patients, a total of 22,211 patients were available for analy-
sis (Fig. 1).
Clinical data
Patient demographic data, medical history, risk factors, 
physical data, and indications for CCTA were collected 
before each CCTA examination in site-specific case report 
forms. Standardized definitions for cardiovascular risk 
factors were used [12]. National Cholesterol Education 
Program (NCEP) risk was calculated using age, gender, 
symptoms, and risk factors (smoking, hypertension, dys-
lipidemia, diabetes, and family history of premature CAD) 
[13–15].
Fig. 1  Study flow diagram
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CCTA image acquisition and analysis
CCTAs were performed with ≥ 64-detector row scanner, and 
included both single-source and dual-source scanners. Image 
acquisition, post-processing, and interpretation for CCTAs 
in the CONFIRM cohort were in compliance with each site’s 
institutional policy or SCCT guidelines [12, 16]. CAC scores 
were calculated by the method of Agatston [17]. Standard 
post-processing techniques were used to determine the pres-
ence and extent of CAD, with obstructive CAD defined as a 
luminal diameter stenosis ≥ 50%. Coronary artery anatomy 
and the extent of atherosclerotic plaque were assessed using 
a 17-segment model of the coronary arteries (Fig. 2) [16].
Calculation of aSIS
SIS was calculated as the total number of coronary seg-
ments with atherosclerotic plaque (irrespective of sever-
ity). aSIS was calculated as the quotient between SIS and 
the total number of segments that was evaluable for plaque, 
multiplied by 100, and adjusted by dividing by patient age 
(aSIS = ([SIS/total number of evaluable segments] × 100)/
age) (Fig. 2). To obtain clinically applicable categoriza-
tion, the cohort was divided into four categories of aSIS. 
All aSIS = 0 (no atherosclerosis) were assigned into the first 
category, and the remaining were divided into 3 categories 
based on cutoffs derived from our previous single-center 
study [11].
Patient follow‑up and outcome measure
All patients were followed for all-cause death, the pre-spec-
ified outcome for the CONFIRM registry, by local institu-
tions through a dedicated physician or research nurse or both 
[12]. Death was ascertained by query of the National Death 
Index in US sites, and in non-US sites by direct interview 
or telephone contact with the patient’s immediate family or 
primary physician or review of medical records [12]. As the 
National Death Index data do not include the cause of death, 
no data for cardiac death were available for analysis.
Statistical analysis
Absolute counts and percentages were presented for cat-
egorical variables, and continuous variables were pre-
sented as mean ± standard deviation (SD) for normally 
distributed data and medians [interquartile range (IQR)] 
for skewed data. The Wilcoxon rank sum test was used for 
continuous variables and Chi-square test for categorical 
variables. Univariable and multivariable analyses were 
Fig. 2  Coronary artery tree, 
17 segment model. In a case 
of a 45-year-old who has 
plaque in 3 of 17 segments 
(circled), SIS would be 3 and 
aSIS 0.39. Whilst current data 
would suggest SIS < 5 portends 
lower risk than SIS ≥ 5 [2, 5], 
applying aSIS re-stratifies this 
younger patient into the highest 
risk category, suggesting more 
extensive CAD for age
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performed to assess the prognostic value of aSIS for all-
cause death. Any risk factor or CT parameter that had sta-
tistically significant (p < 0.05) association for mortality on 
univariable analysis was included in the subsequent multi-
variable modeling. Cox proportional hazard models were 
performed for risk-adjusted analyses to evaluate the inde-
pendent prognostic value of aSIS and construct adjusted 
survival curves. Statistically significant increases in the 
global Chi-square value and comparisons with global 
model fit using likelihood ratio tests were used to assess 
the incremental prognostic value of models with and with-
out aSIS.
C-index of Harrell was assessed to determine the ability 
of models with aSIS to predict mortality [18]. Improve-
ment in the prediction performance for mortality of a 
model that adds aSIS to clinical risk factors and presence 
of obstructive CAD was evaluated with the net reclassifi-
cation improvement (NRI) index [19]. Category-free NRI 
which defines upward and downward movement as any 
change in the predicted probabilities was reported as a 
measure of discrimination with 95% confidence intervals, 
as it is not influenced by correct scaling of the model and 
is more generalizable [20]. The integrated discrimina-
tion improvement (IDI) and relative IDI were calculated 
to quantify the added predictive ability of models that 
included obstructive CAD and aSIS sequentially to clinical 
predictors. SAS Version 9.3 software (SAS Institute Inc., 
Cary, NC) was used to perform statistical calculations, 
with statistical significance defined as p < 0.05.
Results
Patient characteristics
A total of 22,211 patients (mean age 58.5 ± 12.7 years, 
55.8% male) were identified with median follow-up time of 
27.3 months (IQR 17.8, 35.4) (Table 1). The follow-up rate 
for mortality was 96.5% in the CONFIRM cohort. Patients 
included in the analysis had a median aSIS of 0.16 (IQR 
0.00, 0.47), and median SIS of 1.0 (IQR 0.0, 4.0). There 
was no visible coronary atherosclerosis (SIS and aSIS = 0) 
in 8763 (39.5%) patients.
Based on the previous work, patients were stratified into 
4 categories (aSIS = 0, 0.001–0.314, 0.314–0.699, ≥ 0.700) 
[11]. Patients falling into, respectively, higher aSIS cat-
egory had increasing rates of cardiovascular risk factors 
(diabetes, hypertension, hypercholesterolemia, smok-
ing, and family history) and were more likely to be male 
(Table 1). Additionally, those in the highest aSIS cate-
gory (≥ 0.700) were more likely to have obstructive CAD 
(72%).
Clinical outcome
A total of 368 patients had the clinical outcome of death 
(Figs. 3, 4). Forty-nine (0.6%) events were observed in the 
aSIS = 0 category (AER = 0.20%). 106 events (2.0%) were 
observed in the aSIS < 0.314 category (AER = 0.61%), 116 
(2.3%) in the aSIS 0.314–0.699 category (AER = 0.78%), 
and 97 (3.2%) in the aSIS ≥ 0.700 category (AER = 1.08%) 
(Fig. 4).
Univariable analysis
Comparing patients with and without the clinical outcome, 
those who died were more likely to have hypertension [HR 
1.93 (1.56–2.40), p < 0.001], diabetes [HR 1.74 (1.38–2.19), 
p < 0.001], and smoking history [HR 1.88 (1.52–2.32), 
p < 0.001] (Table 2). History of dyslipidemia and chest 
pain appeared to have lower mortality. In patients with 
dyslipidemia, this observation might be attributed to statin 
therapy. The protective nature of chest pain may be due to 
higher prevalence of non-cardiac chest pain, and treatment 
of symptomatic CAD with either optimal medical therapy 
or revascularization.
Number of segments with obstructive CAD (≥ 50% ste-
nosis) was associated with HR 1.28 (1.23–1.33) for all-cause 
mortality, which was similar to, but slightly more predictive 
than that of SIS, with HR 1.22 (1.18–1.25), both p < 0.001. 
aSIS was most predictive of mortality with HR 3.68 
(2.97–4.56), p < 0.001, followed by presence of obstruc-
tive CAD, with HR 3.11 (2.54–3.82), p < 0.001 (Table 2). 
In subjects ≤ 50 years of age (n = 5702, 36 deaths) aSIS 
had HR 4.62 (2.62–8.15), whereas in those > 50 years old 
(n = 16,509, 332 deaths) HR was 3.22 (2.53–4.11), both 
p < 0.001.
Multivariable analysis
Cox proportional hazard modeling was performed to assess 
the prognostic value of aSIS over clinical predictors and 
obstructive CAD (Table 3). aSIS had HR 2.40 (1.83–3.16) 
for all-cause death, p < 0.001, and Harrell C-statistic 0.723 
(0.700–0.756) when applied in addition to clinical risk 
factors and obstructive CAD (≥ 50%). Use of aSIS cat-
egory to predict all-cause death was associated with HR 
of 1.52 (1.36–1.71), p < 0.001 and Harrell C-statistic 0.735 
(0.707–0.762).
Reclassification statistics
Category-free NRI was used to examine the ability of 
aSIS to appropriately reclassify patient risk for death. 
aSIS as a continuous variable had a category-free NRI of 
0.36 (0.26–0.47), p < 0.001, for all-cause death when used 
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in addition to clinical predictors and obstructive CAD 
(Table 3). IDI and relative IDI are also reported in Table 3, 
and taken together, addition of obstructive CAD has a sig-
nificant incremental reclassification effect over the model 
of clinical risk factors only, and the addition of aSIS has a 
further significant incremental reclassification effect over the 
model of clinical risk factors and obstructive CAD.
Higher aSIS category was also incremental over clini-
cal predictors and obstructive CAD with NRI of 0.34 
(0.24–0.44), p < 0.001. In 2 separate models used to compare 
Table 1  Patient characteristics
a n = 17,730
b n = 18,754
c n = 17,601
d 10-year absolute risk of cardiovascular event
e n = 12,476
All patients 
(n = 22,211)
aSIS = 0 (n = 8763) aSIS 0.001–0.313 
(n = 5420)
aSIS 0.314–0.699 
(n = 5009)
aSIS ≥ 0.700 
(n = 3019)
p value
Median follow-up 
(months)
24.9 (17.8, 35.4) 28.0 (17.9, 37.8) 27.5 (18.0, 36.1) 26.5 (17.9, 33.3) 25.9 (17.5, 33.2) < 0.001
Age 58.5 ± 12.7 51.9 ± 12.4 61.8 ± 11.2 63.4 ± 10.9 63.0 ± 10.6 < 0.001
Male gender 12,403 (55.8%) 3967 (45.3%) 3016 (55.6%) 3186 (63.1%) 2234 (74.0%) < 0.001
Body mass index 
(kg/m2)a
27.1 ± 5.0 26.7 ± 5.1 27.0 ± 5.0 27.2 ± 4.9 27.8 ± 5.0 < 0.001
Cardiac risk factors
 Smoker/ex-smoker 6471 (29.1%) 2247 (25.6%) 1445 (26.7%) 1569 (31.3%) 1210 (40.1%) < 0.001
 Hypertension 11,585 (52.2%) 3767 (43.0%) 2955 (54.5%) 2918 (58.3%) 1945 (64.4%) < 0.001
 Dyslipidemia 12,362 (55.7%) 4016 (45.8%) 3054 (56.3%) 3144 (62.8%) 2148 (71.1%) < 0.001
 Diabetes 3876 (17.5%) 1057 (12.1%) 949 (17.5%) 1119 (22.3%) 751 (24.9%) < 0.001
 Family history of 
CAD
7979 (35.9%) 2911 (33.2%) 1893 (34.9%) 1906 (38.1%) 1269 (42.0%) < 0.001
Symptoms
 Chest  painb 12,281 (55.3%) 5396 (61.6%) 2750 (50.7%) 2508 (50.1%) 1630 (54.0%)
  Non-anginal chest 
pain
1636 (8.6%) 673 (8.6%) 383 (8.9%) 342 (8.5%) 238 (8.6%) 0.152
  Atypical angina 7596 (40.1%) 3638 (46.2%) 1675 (38.9%) 1379 (34.3%) 904 (32.8%) < 0.001
  Typical angina 3049 (16.1%) 1085 (13.8%) 689 (16.0%) 787 (19.6%) 488 (17.7%) < 0.001
 Dyspneac 5079 (28.9%) 1990 (27.5%) 1170 (29.1%) 1174 (31.3%) 745 (28.7%) 0.001
NCEPd
 Low risk (< 10%) 6037 (27.2%) 3609 (41.2%) 1238 (22.8%) 819 (16.4%) 371 (12.3%) < 0.001
 Intermediate risk 
(10–20%)
11,610 (52.3%) 3945 (45.0%) 3132 (57.8%) 2885 (57.6%) 1648 (54.6%) < 0.001
 High risk (> 20%) 4564 (20.5%) 1209 (13.8%) 1050 (19.4%) 1305 (26.1%) 1000 (33.1%) < 0.001
Medications
 Beta-blocker 4093 (30.9%) 1257 (23.1%) 983 (31.9%) 1006 (37.3%) 847 (42.3%) < 0.001
 Aspirin 5479 (41.4%) 1561 (28.6%) 1418 (46.1%) 1462 (54.2%) 1038 (51.8%) < 0.001
 ACE-inhibitor 2073 (15.7%) 561 (10.3%) 477 (15.5%) 506 (18.7%) 529 (26.4%) < 0.001
 Statin 5211 (39.3%) 1256 (23.0%) 1319 (42.8%) 1430 (52.9%) 1206 (60.1%) < 0.001
LV  parameterse
 LV ejection frac-
tion (%)
62.0 ± 12.5 60.9 ± 12.3 62.2 ± 12.1 62.9 ± 12.5 62.2 ± 13.4 0.001
 Normal LVEF 
(≥ 50%)
10,623 (85.1%) 4158 (87.3%) 2432 (85.4%) 2437 (83.9%) 1596 (81.5%) < 0.001
Obstructive CAD 5749 (25.9%) 2 (0.0%) 1216 (22.4%) 2358 (47.1%) 2173 (72.0%) < 0.001
SIS 1.00 (0.00, 4.00) 0.00 (0.00, 0.00) 1.00 (1.00, 2.00) 4.00 (3.00, 5.00) 7.00 (6.00, 9.00) < 0.001
%SIS 8.33 (0.00, 28.57) 0.00 (0.00, 0.00) 8.33 (7.69, 15.38) 28.57 (23.08, 35.71) 58.33 (50.00, 72.73) < 0.001
aSIS 0.16 (0.00, 0.47) 0.00 (0.00, 0.00) 0.18 (0.13, 0.25) 0.47 (0.39, 0.58) 0.93 (0.80, 1.12) < 0.001
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risk reclassification in addition to traditional clinical risk 
factors, aSIS demonstrated similar ability to reclassify 
patient risk as the presence of obstructive CAD, with NRI of 
0.46 (0.36–0.56) for the model ‘clinical risk + aSIS’ versus 
0.48 (0.37–0.58) for the model ‘clinical risk + obstructive 
CAD’, p < 0.001.
Sub‑analysis in patients with obstructive 
and non‑obstructive CAD
aSIS was associated with highest risk for mortality, with 
highest hazard ratios for both patients with non-obstructive 
CAD and obstructive CAD (Tables 4, 5, 6). Importantly, in 
the population with non-obstructive CAD, aSIS had signifi-
cantly higher HR for mortality than SIS or age alone.
Discussion
Using the CONFIRM registry, the independent and incre-
mental prognostic value of aSIS was validated over routine 
clinical measures and CCTA measure of obstructive CAD. 
Higher aSIS categories were associated with increased risk 
of all-cause mortality (HR 2.40 (1.83–3.16), p < 0.001, and 
NRI of 0.36 (0.26–0.47), p < 0.01).
Previous work demonstrated that aSIS (also termed 
%TPS/age) score has an incremental prognostic value for 
MACE over traditional risk factors and conventional CCTA 
assessment of coronary atherosclerosis [11]. We hypothe-
sized that this novel measure, which can be quickly and eas-
ily derived from routine clinical CCTA, may be a surrogate 
marker of coronary vascular age. Although the prevalence 
of traditional risk factors and obstructive CAD increased 
with aSIS category, two-thirds of patients in the highest 
aSIS category had low or intermediate NCEP risk (Table 1); 
hence confirming the potential limitations of routine clinical 
risk predictors and the potential utility of aSIS to reclassify 
patient risk.
CCTA, extent of CAD, and prognosis
Framingham risk factors have only moderate correlation 
with atherosclerosis burden; a significant proportion of 
patients with low and intermediate Framingham risk have 
coronary atherosclerosis demonstrated by CCTA [21]. Ana-
tomic evaluation of coronary arteries by CCTA allows early 
identification of coronary artery disease that may be subclin-
ical and undetectable by functional testing, but is often the 
substrate of MACE [22, 23]. The presence of non-obstruc-
tive CAD on CCTA is associated with higher mortality even 
adjusting for CAD risk factors, with highest risk seen in 
those with greater extent of non-obstructive CAD [2, 4, 5]. 
SIS is a simple and reproducible semiquantitative measure 
quantifying the extent of CAD burden on CCTA (irrespec-
tive of degree of stenosis). Extent of CAD is a strong predic-
tor of events [24], and SIS ≥ 5 on CCTA has been shown to 
have worse prognosis that is comparable to the presence of 
obstructive CAD [2, 5].
Coronary vascular age and atherosclerosis 
that is extensive for age
SIS and extent of CAD increase with age [25, 26]. Ath-
erosclerosis begins in the early decades of life [27], and 
may remain clinically silent for decades until plaque ero-
sion and rupture result in clinical events or lesions become 
obstructive resulting in ischemia. However, individuals with 
more rapid development of coronary atherosclerosis have 
Fig. 3  Annual event rates for mortality by aSIS category for the entire 
cohort (n = 22,211). Mortality comparison between aSIS categories 
had p < 0.001 for all comparisons, except between 0.001–0.313 cat-
egory and 0.314–0.699 category (p = 0.05)
Fig. 4  Risk-adjusted survival curves by aSIS category, p < 0.001. 
aSIS = 0 category, whilst included in the continuous variable analysis, 
was not included in this figure as it was used as a reference for out-
comes for the other aSIS categories
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an increased rate of adverse outcomes [8–10, 28]. Absolute 
plaque measurements may estimate 10-year risk which is 
independent of age; however, adjusting plaque burden to 
age gives a greater weighting for each involved segment if 
younger and may be a potential estimate of lifetime risk. 
For example, a 30-year-old and 60-year-old who have the 
same plaque burden and CAC theoretically may have the 
same 5–10 year risk; however, the 30-year-old would have 
atherosclerotic disease that has developed more rapidly and 
is more extensive for their age, and aSIS may act as a marker 
of vascular age and provide enhanced prediction of lifetime 
risk.
Clinical implications
The simplicity of SIS gives the potential for it to be calcu-
lated by automated software algorithms. Itss adjustment to 
age as aSIS may offer a method of enhanced risk stratifica-
tion and prognostication by CCTA. With advancements in 
CT technology and novel scanning algorithms promising 
ongoing reduction in radiation dose and increasing use of 
CCTA, aSIS uses information readily available and easily 
calculable from clinical scans that may identify patients with 
‘greater vascular age’ or atherosclerosis that is more exten-
sive for age, and at greater risk of mortality. Additionally, 
aSIS may be a sensitive marker of subclinical (non-obstruc-
tive) disease, removing a false sense of security for some 
at-risk patients, and so improve adherence to preventative 
measures.
CT evaluation of coronary atherosclerosis impacts 
downstream testing and management, influences physician 
behavior, and results in better risk factor modification and 
increased medical therapy [29–31]. The use of statins has 
been associated with reduced risk for mortality in patients 
with non-obstructive disease on CCTA [32, 33]. Bittencourt 
et al. have shown that extent of plaque detected by CCTA 
enhances risk assessment, and even patients with non-
obstructive disease and SIS > 4 had significant increase in 
events; it is thus possible that statins may reduce mortality 
in patients with higher aSIS [5].
Whilst there is a lack of prospective data, aSIS could 
be a useful tool for triaging medical therapy. Further 
prospective studies are needed to understand the clinical 
role of aSIS, and potential economic benefits. However, 
Table 2  Univariable analysis for mortality
a n = 17,730
b n = 18,754
c n = 17,601
d n = 12,476
All-cause death (n = 368) No all-cause death 
(n = 21843)
Hazard ratio (95% CI) p value
Male gender 218 (58.7%) 12,187 (55.8%) 1.12 (0.91–1.38) 0.292
Body mass index (kg/m2)a 26.0 ± 5.5 27.1 ± 5.0 0.98 (0.95–1.00) 0.070
Cardiac risk factors
 Smoker/ex-smoker 140 (38.0%) 6331 (29.0%) 1.88 (1.52–2.32) < 0.001
 Hypertension 245 (66.6%) 11,340 (51.9%) 1.93 (1.56–2.40) < 0.001
 Dyslipidemia 178 (48.4%) 12,184 (55.8%) 0.72 (0.59–0.88) 0.001
 Diabetes 101 (27.4%) 3775 (17.3%) 1.74 (1.38–2.19) < 0.001
 Family history of CAD 121 (32.9%) 7858 (36.0%) 1.24 (0.99–1.54) 0.057
NCEP 1.88 (1.61, 2.19) < 0.001
 Low risk 45 (12.2%) 5991 (23.3%)
 Intermediate risk 194 (52.7%) 12,317 (56.4%)
 High risk 129 (35.1%) 4435 (20.3%)
Chest  painb 161 (44.6%) 11,754 (53.8%) 0.64 (0.51–0.81) < 0.001
Dyspneac 112 (30.4%) 4967 (22.7%) 2.19 (1.72–2.79) < 0.001
Abnormal LVEF (≤ 50%)d 72 (19.6%) 1781 (8.2%) 2.35 (1.78–3.11) < 0.001
Obstructive CAD (≥ 50%) 182 (49.5%) 5567 (25.5%) 3.11 (2.54–3.82) < 0.001
Age 69.0 ± 12.7 58.3 ± 12.3 1.09 (1.08–1.10)  < 0.001
SIS 4.00 (2.00, 6.00) 1.00 (0.00, 4.00) 1.22 (1.18–1.25) < 0.001
%SIS 28.57 (14.29, 50.00) 8.33 (0.00, 28.57) 1.03 (1.02–1.03) < 0.001
aSIS 0.38 (0.19, 0.73) 0.15 (0.00, 0.47) 3.68 (2.97–4.56) < 0.001
aSIS category 2.7 ± 1.0 2.1 ± 1.1 1.75 (1.59–1.92) < 0.001
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findings from this study placed in the context of available 
CT data would suggest that higher aSIS warrants closer 
clinical surveillance and follow-up, and more aggressive 
institution of preventative measures including lifestyle 
modifications, more aggressive risk factor control, and 
consideration of statin therapy [5, 11, 29, 30, 33].
Limitations
Ideally direct measures of plaque progression would pro-
vide us with information regarding true rates of change 
and how they may be attenuated with medical therapy. In 
the absence of such tests, aSIS may be a reasonable marker 
Table 4  Univariable analysis 
for mortality in patients with 
non-obstructive CAD and 
obstructive CAD
a n = 4453
b n = 4584
c n = 4405
Non-obstructive CAD
Hazard ratio (95% CI)
p value Obstructive CAD
Hazard ratio (95% CI)
p value
Male gender 0.99 (0.73–1.34) 0.932 0.96 (0.72–1.27) 0.754
Body mass index (kg/m2)a 0.92 (0.88–0.96) < 0.001 1.01 (0.97–1.04) 0.738
Cardiac risk factors
 Smoker/ex-smoker 1.52 (1.13–2.04) 0.005 1.78 (1.31–2.42) < 0.001
 Hypertension 1.33 (0.98–1.81) 0.070 2.18 (1.61–2.95) < 0.001
 Dyslipidemia 0.66 (0.49–0.88) 0.005 0.67 (0.50–0.89) 0.006
 Diabetes 1.12 (0.82–1.54) 0.474 1.93 (1.39–2.69) < 0.001
Family history of CAD 0.84 (0.61–1.15) 0.281 1.51 (1.11–2.04) 0.009
NCEP 1.41 (1.13–1.76) 0.003 1.96 (1.61–2.40) < 0.001
 Low risk
 Intermediate risk
 High risk
Chest  painb 0.80 (0.57–1.11) 0.184 0.54 (0.39–0.76) < 0.001
Dyspneac 1.68 (1.20–2.36) 0.003 2.36 (1.68–3.31) < 0.001
SIS 1.13 (1.08–1.18) < 0.001 1.22 (1.16–1.28) < 0.001
Age 1.07 (1.06–1.09)  < 0.001 1.08 (1.07–1.09)  < 0.001
%SIS 1.02 (1.01–1.02) < 0.001 1.03 (1.02–1.03) < 0.001
aSIS 1.72 (1.20–2.45) 0.003 3.84 (2.59–5.70) < 0.001
aSIS category 1.37 (1.13–1.67) 0.002 1.59 (1.39–1.83) < 0.001
Table 5  Cox models for mortality in patients with obstructive CAD
Only variables with a univariate p < 0.05 including all patients were included in the Cox regression model
a Continuous variable
Hazard ratios 
(95% CI)
p value Global 
Chi-
square
Harrell C-statis-
tic (95% CI)
NRI NRI p value IDI IDI p value Relative IDI
Clinical 16.38 0.560 (0.523–
0.659)
– – – – –
 Smoker/ex-
smoker
1.57 (1.17–2.11) 0.003
 Dyslipidemia 0.64 (0.48–0.86) 0.003
Clinical + aSISa 25.85 0.599 (0.548–
0.651)
0.122 
(− 0.025–
0.269)
0.105 0.003 
(0.000–
0.005)
0.031 33.88%
 Smoker/ex-
smoker
1.48 (1.10–2.00) 0.010
 Dyslipidemia 0.60 (0.44–0.80) 0.001
 aSISa 1.79 (1.25–2.58) 0.002
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of premature atherosclerosis that is extensive for age. Age 
was removed from the multivariable analysis to avoid col-
linearity with aSIS, as age is part of the score; however, in 
the univariable analysis, aSIS score was a superior predic-
tor of mortality than age, SIS or %SIS alone with much 
higher hazard ratios. Further studies are needed to better 
understand how such measures can be used to guide medi-
cal therapy. Although aSIS was prognostic for MACE in 
our previous study, not all CONFIRM centers were able 
to collect MACE. Therefore, all-cause mortality was the 
pre-specified primary end point for the CONFIRM registry 
[12]. Breakup of cause of death was not available from the 
query of the National Death Index for US sites.
Conclusion
aSIS may be a surrogate marker for vascular age and has 
independent and incremental prognostic value for all-cause 
mortality over traditional risk factors, obstructive CAD on 
CCTA. Further studies are needed to understand how it can 
be incorporated into clinical practice and how it might direct 
preventative measures.
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